Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-label, Multicenter, Dose-escalation Study of CK-301 Administered Intravenously as a Single Agent to Subjects With Advanced Cancers

X
Trial Profile

A Phase 1, Open-label, Multicenter, Dose-escalation Study of CK-301 Administered Intravenously as a Single Agent to Subjects With Advanced Cancers

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cosibelimab (Primary)
  • Indications Cancer; Colorectal cancer; Endometrial cancer; Head and neck cancer; Hodgkin's disease; Laryngeal cancer; Malignant melanoma; Merkel cell carcinoma; Mesothelioma; Mouth neoplasm; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Pharyngeal neoplasms; Renal cell carcinoma; Skin cancer; Small cell lung cancer; Squamous cell cancer; Urogenital cancer
  • Focus Adverse reactions; First in man; Registrational; Therapeutic Use
  • Sponsors Checkpoint Therapeutics
  • Most Recent Events

    • 29 Jan 2024 According to a Checkpoint Therapeutics media release, The company plans to resubmit BLA application based on data from this trial.
    • 18 Dec 2023 According to a Checkpoint Therapeutics media release, the U.S. Food and Drug Administration has issued a complete response letter for the cosibelimab biologic license application for the treatment of patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or radiation.
    • 18 Oct 2023 According to a Checkpoint Therapeutics media release, data (n=78) from this study were published in the in the Journal for ImmunoTherapy of Cancer (JITC), the peer-reviewed, online journal of the Society of Immunotherapy of Cancer.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top